Page 1,874«..1020..1,8731,8741,8751,876..1,8801,890..»

FDA expected to approve drug that halts multiple sclerosis in some patients – The Columbus Dispatch

Posted: Published on March 27th, 2017

JoAnne Viviano The Columbus Dispatch @JoAnneViviano Nathan Frim calls Dr. Michael Racke a miracle worker. The 44-year-old Frim, who has multiple sclerosis, used to take a pill every day, but his disease progressed. In the past, there wasn't much Racke or other doctors could do. But along came a drug called ocrelizumab. It's Racke's magic wand. The drug, expected to be approved by the U.S. Food and Drug Administration today, has been shown to halt the disease in patients with both relapsing MS and primary progressive MS, said Racke, a neurologist at Ohio Sate University's Wexner Medical Center. "It brings peace of mind," said Frim, who has relapsing MS. "Being on this medicine, I'm not worried about the progression. I feel that that's not an issue for me right now." Further, the dosing schedule an infusion every six months gives him a reprieve from worrying about the disease that doctors discovered he had in December 2014. For days at a time, he said, he doesn't even think about having MS. Frim, of Sunbury, received his latest dose of ocrelizumab on March 17.He's one of about 70 patients receiving the drug at Ohio State as part of clinical trials by drugmaker … Continue reading

Posted in MS Treatment | Comments Off on FDA expected to approve drug that halts multiple sclerosis in some patients – The Columbus Dispatch

Decreased Mortality, CAC Scores With Hormone Replacement Therapy – Endocrinology Advisor

Posted: Published on March 27th, 2017

Decreased Mortality, CAC Scores With Hormone Replacement Therapy Endocrinology Advisor At the time of the CAC scan, 41% of women reported taking HRT. These patients were younger (70.6 vs 63.5 years; P <.001) and had a lower prevalence of hypertension and diabetes. Although there were no differences in total or low-density lipoprotein ... See original here: Decreased Mortality, CAC Scores With Hormone Replacement Therapy - Endocrinology Advisor … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on Decreased Mortality, CAC Scores With Hormone Replacement Therapy – Endocrinology Advisor

Potential of stem cell therapy to repair lung damage – Science Daily

Posted: Published on March 27th, 2017

ScrollToday Potential of stem cell therapy to repair lung damage Science Daily Researchers delivered stem cells intravenously to b-ENaC overexpressing mice at 4 and 6 weeks of age, before collecting samples tissue and cells from the lungs at 8 weeks. They compared these findings to a control group that did not receive the MSC ... Study shows potential of stem cell therapy to repair lung damageEurekAlert (press release) Soon, stem cells may repair lung damageFree Press Journal all 10 news articles » The rest is here: Potential of stem cell therapy to repair lung damage - Science Daily … Continue reading

Posted in Stem Cell Research | Comments Off on Potential of stem cell therapy to repair lung damage – Science Daily

Stem cells shown to restore erection capability in men with erectile dysfunction – Science Daily

Posted: Published on March 27th, 2017

Men's Health Stem cells shown to restore erection capability in men with erectile dysfunction Science Daily The research group, from Odense in Denmark, used stem cells taken from abdominal fat cells via liposuction (under a general anaesthetic): none of the 21 men reported significant side effects over the trial period, or in the following year. After ... This Might Be the New Cure For Erectile DysfunctionMen's Health Just ONE injection of stem cells from a man's stomach could be a permanent cure for impotence (and even help them to ...Daily Mail all 7 news articles » View original post here: Stem cells shown to restore erection capability in men with erectile dysfunction - Science Daily … Continue reading

Posted in Stem Cell Research | Comments Off on Stem cells shown to restore erection capability in men with erectile dysfunction – Science Daily

Why Cellect Biotechnology Stock Is Skyrocketing Today – Motley Fool

Posted: Published on March 27th, 2017

What happened Cellect Biotechnology (NASDAQ:APOP), an Israeli-based stem-cell company, today announced the first successful stem cell transplant procedure using its ApoGraft technology in a combined phase 1/2 clinical trial in a blood cancer patient, causing its shares to rise by as much as 115%. The company's stock has since cooled off, but is still up by 80% as of 3:00 p.m. EDT. Image source: Getty Images. Even though stem cell transplants can be a curative treatment for many blood disorders and blood-related cancers, they tend to be a treatment of last resort because of their life-threatening side effects, such as graft-versus-host disease (GvHD). So, if Cellect's ApoGraft technology turns out to be a viable workaround, it would be a major advancement in the field, and potentially an extremely lucrative product for the company. While Cellect's announcement is indeed exciting, its stock still isn't a great long-term bet. Cellect exited 2016 with a paltry $8 million in cash andApoGraft is probably five to six years away from reaching the market. This current trial, after all, is simply a safety and proof-of-concept study that's not designed to provide a basis for a regulatory approval. In addition, Bellicum Pharmaceuticals'adjunct T-cell therapy BPX-501 could … Continue reading

Posted in Biotechnology | Comments Off on Why Cellect Biotechnology Stock Is Skyrocketing Today – Motley Fool

Biotechnology Gets A Shot In the Arm – Barron’s

Posted: Published on March 27th, 2017

Biotechnology Gets A Shot In the Arm Barron's The healthcare sector has been doing rather well, gaining 8.9% year-to-date. Behind just information technology, healthcare stocks have outpaced Trump sectors including materials, industrials, and financials so far, suggesting that investors may be ... iShares Nasdaq Biotechnology (IBB) volatility low into Credit Suisse ...StreetInsider.com iShares NASDAQ Biotechnology Index (IBB) Rating Increased to ...BBNS all 5 news articles » Excerpt from: Biotechnology Gets A Shot In the Arm - Barron's … Continue reading

Posted in Biotechnology | Comments Off on Biotechnology Gets A Shot In the Arm – Barron’s

First successful stem cell cancer transplant sees Cellect Biotechnology shares surge – Proactive Investors USA & Canada

Posted: Published on March 27th, 2017

Cellect Biotechnology Ltd (NASDAQ:APOP, TASE:APOP) shares shot up 74% in New York after it successfully performed the first stem cell transplant procedure on a cancer patient. It happened in the group's phase I/II clinical trial in a blood cancer patient. The stem cell firm's chief executive Dr Shai Yarkoni said: After 15 years of research, this is the first time we have used our technology on a cancer patient suffering from life-threatening conditions. "It is a first good step on a road that we hope will lead to stem cell based regenerative medicine becoming a safe commodity treatment at every hospital in the world. Up to half of all stem cell transplant procedures, such as bone marrow transplants, result in life-threatening rejection disease, known as Graft-versus-Host-Disease (GvHD). But the firm's ApoGraft technology aims to stop all that. Now, the independent data and safety monitoring board (DSMB) has approved the enrolment of two further patients for the ApoGraft treatment to complete the first study cohort as planned. Shares shot up 74% to reach $10.9 each. Register here to be notified of future PROAC Company articles Continued here: First successful stem cell cancer transplant sees Cellect Biotechnology shares surge - Proactive Investors … Continue reading

Posted in Biotechnology | Comments Off on First successful stem cell cancer transplant sees Cellect Biotechnology shares surge – Proactive Investors USA & Canada

YaleNews | Ronald Breaker named Sterling Professor of Molecular … – Yale News

Posted: Published on March 27th, 2017

Ronald R. Breaker, newly named as a Sterling Professor of Molecular, Cellular and Developmental Biology, is one of the worlds experts on the diversity and function of RNAs, which are crucial to carrying out a host of life processes.Breaker is best known for his discovery of riboswitches, elements of RNA that can control the expression of genes. A Sterling Professorship is one of the universitys highest faculty honors. A graduate of the University of Wisconsin-Stevens Point, Breaker earned his Ph.D. from Purdue University. He conducted postdoctoral research at The Scripps Research Institute, pioneering a variety of test-tube evolution strategies to isolate novel RNA enzymes. He was the first to create catalytic DNAs or deoxyribozymes using this technology. Since establishing his laboratory at Yale in 1995, Breaker has continued to conduct research on the advanced functions of nucleic acids, including ribozyme reaction mechanisms, molecular switch technology, next-generation biosensors, and catalytic DNA engineering. His laboratory has established the first proofs that metabolites are directly bound by messenger RNA elements called riboswitches; discovered more than 40 distinct classes of these RNA gene control elements; and published the first studies validating riboswitches as targets for antibiotics. Prior to his new appointment, Breaker was the … Continue reading

Posted in Biology | Comments Off on YaleNews | Ronald Breaker named Sterling Professor of Molecular … – Yale News

Cell biology: The quickest route to the tip for protein transport – Science Daily

Posted: Published on March 27th, 2017

Cell biology: The quickest route to the tip for protein transport Science Daily Cell biology: The quickest route to the tip for protein transport. Date: March 27, 2017; Source: Ludwig-Maximilians-Universitt Mnchen; Summary: According to a new theoretical model, in cell protrusions and cargo-transporting motor proteins often get ... and more » View original post here: Cell biology: The quickest route to the tip for protein transport - Science Daily … Continue reading

Posted in Biology | Comments Off on Cell biology: The quickest route to the tip for protein transport – Science Daily

Can a new model help governance keep up with synthetic biology? – PLoS Blogs (blog)

Posted: Published on March 27th, 2017

Synthetic biology is moving at a rapid pace, and regulations will need to keep up to allow useful technologies to hit the market while maintaining a high standard of safety. Since mostpolicymakers are not experts in all of the newest synthetic biology technologies, better analysis tools are needed to understand how to react. Sotworesearchers, ChristopherCummings and Jennifer Kuzma, from North Carolina State University and Nanyang Technological University builta model to determine how to prepare for handling the regulation new synthetic biology products. This model for assessing risks of new synthetic biology technologies is called Societal Risk Evaluation Scheme (SRES) and it tries to make governance more anticipatory than just reactive. This is a tough problem. How do we predict the risks of technologies that dont exist yet? How do we assess products that seem totally new? The field of synthetic biology is pushing the boundaries of what we can do with and to biology. To createthe model the researchers used a Delphi study,which is a structured way of developing forecasts and assessments using a panel of experts. Their Delphi study used four rounds: 1) Standardized open-ended interview to get qualitative data. 2) Online quantitative survey using questions formed using rounds … Continue reading

Posted in Biology | Comments Off on Can a new model help governance keep up with synthetic biology? – PLoS Blogs (blog)

Page 1,874«..1020..1,8731,8741,8751,876..1,8801,890..»